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INTRODUCTION
Historically, family planning programs and studies
have focused on women. Studies on male-involve-
ment in family planning has increased contracep-
tion use.1 Male contraceptive methods are still lim-
ited, with condoms and vasectomy being the most
widely used method. Condom use in men is ranked
fourth globally but is often used incorrectly and in-
consistently. Vasectomy is an effective and safe
method but not favorable because it is not easily
reversible.2,3 Therefore, there is a need for a new
contraceptive method is effective, reversible, and
acceptable.
Male hormonal contraceptive methods are cons-
tantly being developed. In theory, the male hormonal
contraception works by providing negative feedback
to suppress spermatogenesis. Gonadotropins from
the pituitary will be suppressed by administration of
testosterone or androgen derivative that is often
given in combination with anti-gonadotrophic agent,
such as progestin or GnRH antagonists. Methods of
male hormonal contraception are one of the rever-
sible contraceptive options with high effectiveness
and will be discussed further below.4
The Physiological Basis of Male Fertility
There are 4 aspects that play a role in physiological
basis of male fertility, which are:
The hypothalamic-pituitary axis: control of go-
nadotropin secretion3
The hypothalamic-pituitary-testicular axis with ne-
gative feedback mechanism of the downstream pro-
ducts played the pivotal regulatory role in maintain-
ing homeostasis. Hypothalamus will control pulsatile
GnRH secretion, which regulates pituitary glands to
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produce gonadotropins (follicle stimulating hor-
mone/FSH and luteinizing hormone/LH), whereas
gonadotropins regulates testicular production of
both hormones and sperm. Steroid and peptide hor-
mone produced in the testes will provide a negative
feedback signal to the pituitary and hypothalamus.
Therefore, disruption of GnRH secretion is a poten-
tial target for contraceptive methods.
Researchers found that the G protein receptor GPR
54 plays an important role in the secretion of go-
nadotropin and 54-amino acid peptide kisspeptin-54
(metastin) is the ligand for GPR 54. Subsequent in-
vestigations have demonstrated that kisspeptin ad-
ministration in the brain results in GnRH and go-
nadotropin secretion in animal models and gonado-
tropin secretion can be blocked by administration of
GnRH antagonists. Moreover, the negative feedback
of testosterone and estradiol on GnRH secretion is
mediated via inhibition of kisspeptin production in
the arcuate nucleus of the hypothalamus. Inhibitors
of kisspeptin, GPR 54 agonists and antagonists, in
combination with testosterone in theory may be a
strategy of contraception.
Testosterone is a steroid hormone produced pri-
marly in the testes, but significant aromatase activity
in the testicle and peripheral tissues result in pro-
duction of estradiol as well. Testosterone works by
inhibiting transcription of kisspeptin and GnRH and
gonadotropin secretion. Estradiol also plays an im-
portant role in steroid negative feedback in men, par-
ticularly by decreasing LH production. It is also
known that FSH regulation is more dependent on es-
tradiol compared to testosterone.
The precise role of progesterone in normal male
physiology is unknown, but progesterone receptors
have been demonstrated in the male hypothalamus,
pituitary, and reproductive tract. Additionally pro-
gestin administration enhance male hormonal con-
traceptive efficacy when combined with androgens.
The effect is attributed to increased hypothalamic-
pituitary suppression of gonadotropin secretion
either directly or through the androgen receptor.
Finally, the nonsteroidal testicular product inhibin
B contributes to hormonal feedback in males. In-
hibin B is predominantly produced by Sertoli cells
and will give negative feedback on the production of
FSH. Theoretically, exogenous inhibin B in conjunc-
tion with androgens might further supress FSH, and
can be used as a hormonal male contraceptive regi-
men.
Testosterone production and androgen action3
Testosterone is produced by the Leydig cells in the
testes as a response to LH stimulation. However,
studies in mice have shown evidence that testos-
terone production can also be non-LH dependent.
Therefore, the regulation of testosterone produc-
tion in non-dependent gonadotropin is a critical as-
pect in developing an effective male hormonal con-
traceptive method because hormonal contraception
relies on blockade of gonadotropin secretion for ef-
ficacy.
In experiments, suppression of LH and FSH levels
profoundly decreases testosterone production and
reduces spermatogenesis in men. However, research
on mice with LH-receptor-deficiency show that even
with low androgen levels and further blockade of an-
drogen receptor (flutamide) for complete suppres-
sion of residual androgen action, spermatogenesis
can still occur, which will lead to contraceptive fail-
ure. Further investigation into the precise regulation
and role of intratesticular androgens in supporting
spermatogenesis in men is still needed, because tar-
geted disruption of residual androgen production
and action might be an adjunt to increase effective-
ness of current hormonal methods.
Using a hormonal approach of contraception, tes-
tosterone is given to block gonadotropin secretion
while maintaining nongonadal androgen-dependent
functions such as sexual drive and muscle mass. Sig-
nificant supraphysiological dosing of testosterone can
Figure 1. (A) Spermatogenesis in normal circumstances; (B)
Effects of hormonal contraceptive intervention in the repro-
ductive axis. Source: Page ST, Amory JK, Bremner WJ. Ad-
vances in male contraception. Endocrine reviews. 2008;
29(4): 465-93. PubMed PMID: 18436704. Pubmed Central
PMCID: 2528850
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be associated with side effects, which includes high-
density lipoprotein (HDL) suppression, acne, and in-
creased hemoglobin concentrations that would not
be desirable in a regimen designed or long-term use.
Spermatogenesis3
During spermatogenesis, spermatogonia will un-
dergo 4 stages to develop into mature spermatozoa.
First, type A spermatogonia undergo mitosis, result-
ing in renewal of germline stem cells as well as type
B spermatogonia that continue to undergo differen-
tiation. Secondly, type B spermatogonia undergo
meiosis to become spermatids. Thirdly, there is
spermiogenesis, where mature spermatids become
motile spermatozoa. Fourth, the interaction with
Sertoli cells mediate the spermiation process,
where cytoplasmic material from the spermatid is
removed and the mature sperm will be released
into the lumen of the seminiferous tubules. This
whole process requires regulation of endocrine hor-
mones. FSH and LH are required for the above pro-
cesses.
Epididymis3
Once spermatogenesis has been completed, sperm
are released from the Sertoli cells into the lumen of
the seminiferous tubules, and move through the
epididymis before ejaculation. FSH and testoste-
rone are thought to play a role in spermiation and
the release of spermatid into the tubule lumen. Fail-
ure of spermiation will lead to sperm retention and
phagocytosis by the Sertoli cell. Within the epi-
didymis, sperm undergo further maturation steps,
allowing for maximal motility and fertilization ca-
pacity.
Male Hormonal Contraceptive Mechanism
The mechanism of male hormonal contraceptives is
to inhibit spermatogenesis by suppression of the
hypothalamic-pituitary-testicular axis function. A
reversible azoospermic condition is targeted by this
inhibition.
Hypothalamus secretes gonadotropin-releasing
hormones (GnRH) which stimulates the secretion of
LH and FSH in the pituitary gland. LH binds to Leydig
cells in the testicular interstitium and stimulates the
production of testosterone. The resultant testoste-
rone diffuses into the seminiferous tubules, and in-
duces spermatogenesis, mediated by FSH stimulation
from Sertoli cells. This Testosterone also enters the
bloodstream and, in combination with estradiol,
serves to regulate its own production by negative
feedback at the level of the hypothalamus and pitui-
tary gland.5
This regulation is used as a basic concept of male
hormonal contraception. High level of exogenous tes-
tosterone will lead to inhibition of negative feedback
regulation. It is accepted as a positive feedback in the
hypothalamus and pituitary glands, so that the secre-
tion of LH and FSH will be suppressed, as well as
spermatogenesis. This regulation is expected to be
reversible.
However, in several men, administration of testos-
terone alone fails to completely suppress sperm pro-
duction. Therefore, ongoing study for combination
male hormonal contraceptive still continues.
Male Hormonal Contraceptive Studies
Studies on male hormonal contraception have
started since 1939. Testosterone administration is
used to suppress secretion of LH and FSH from the
pituitary. Low concentrations of these hormones
will inhibit spermatogenesis and results in de-
creased sperm concentrations. First studies re-
vealed reversible azoospermia in some patients
with daily use of testosterone alone regimen ad-
ministered in the duration of 60 days. Improvement
of delivery frequency and dosage are still undergo-
ing studies until now. However, some data have
shown that administration of testosterone alone
regimens fail to completely suppress spermatoge-
nesis in many groups, due to ethnic differences,
body fat content, baseline testosterone levels, dif-
ferent susceptibility of reductase levels for each
groups and other reasons. The fact is, 91% of Asian
and 60% of Caucasian patients become azoosper-
mic due to differences in endocrine response.6
Recent studies still compared between admini-
stration of a testosterone-only regimen and testos-
terone combined with exogenous progestin.
Androgen Only
Testosterone-only administration has many side ef-
fects; including mood changes, weight gain, increase
in hemoglobin and hematocrit, skin problems (oily
skin and acne), decrease in testicular volume,
gynecomastia, sleep apnea, and possible effects on
cholesterol levels.6
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Testosterone Buciclate
Testosterone Buciclate is a long acting testosterone
derivative and have shown moderate effect of sup-
pression of spermatogenesis at a dose of 1200 mg
per month given through intramuscular injection.
The first study was conducted by World Health Or-
ganization (WHO) in 1995, and revealed minimal
side effects. This trial helped in the initiation of
another study combining long acting testosterone
with progesterone derivatives.
Testosterone Enanthate (TE)6,7
The first study conducted by WHO applied a regi-
men of weekly intramuscular injections of 200 mg
Testosterone Enanthate (TE) for a year. As a result,
70% of the 271 patients became azoospermic
within 6 months. The mean time needed for the
process in the development of azoospermia was 3
months, and the mean time to recovery was 3-4
months. There was only one pregnancy occurring
among the azoospermic patients who followed a
12-month efficacy phase. However, 12% of the men
discontinued from the study because of the discom-
fort caused by the weekly intramuscular injections
and also administration of testosterone-only as a
contraceptive purpose failed to suppress spermato-
genesis.
Similar with the first testosterone study con-
ducted by WHO, the second study found some diffi-
culties with the administration of 200 mg intramus-
cular TE for induction phase, and 100 mg weekly in-
tramuscular injections in 399 volunteers. Although
98% patient experienced suppressed spermatogene-
sis to below 3 million sperms per ml, but 25% of
patients discontinued this study due to several rea-
sons, which include weekly injection discomforts.
Testosterone undecanoate (TU)6,7
A more recent multicenter study used a very-long-
acting formulation of testosterone undecanoate
(TU), which can be administered once every 3-4
months for testosterone replacement in men with
hypogonadism. In two large studies in China, 500
mg TU was used as a single contraceptive agent.
The first study enrolled 308 healthy men, and their
partners administered TU once a month for 12
months. During the study, 299 men showed oli-
gospermia with sperm concentrations below 3-mil-
lion sperm/ml ejaculate, whereas nine men did not
show suppression to this extent. As many as 296 of
the subjects entered an efficacy phase, and six sub-
sequently found it necessary to restart other forms
of contraception because of their rising sperm
counts. An overall efficacy rate of 95% was obtained
from this study, with one pregnancy occurring in
the study group. During the recovery period, hor-
monal levels and semen parameters returned to
baseline.
A more recent study also carried out in China en-
rolled 1,045 men and their partners for a 1.5-year
period using 500 mg TU monthly dosage. As a result,
this group showed a 95% rate of spermatogenesis
suppression and 95% contraceptive efficacy rate.
From both studies, TU seems to be a highly accept-
able, effective, safe, and reversible method for male
contraception in healthy fertile Chinese men.
Synthetic Androgens
7α-methyl-19-norestrosterone (MENT)
MENT is synthetic androgen with potent gonado-
tropin inhibitory activity and prostate sparing ef-
fects.8 This synthetic androgen is more potent than
testosterone, it is resistant to 5 α-reduction, and has
diffusion characteristics that make it easy to be ad-
ministered in the form of depot implant. However,
it has a similar side effect profile with testosterone
and only provides partial dose-dependent suppres-
sion of spermatogenesis. Other sources have shown
that MENT has a short half life, making it unsuitable
for long-term injection; and that it does not show
any significant FSH suppression.6
Dimenthandrolone undecanoate
Dimenthandrolone undecanoate is a potent syn-
thetic androgen that has some progestational acti-
vity, which is currently in development for thera-
peutic uses in men. It appears to suppress LH se-
cretion in vitro and in rabbit models. It works
without stimulating prostate growth and is resis-
tant to 5 α-reduction.9
Combined with Progestin
Combination of progestin and androgen replace-
ment therapy as a contraceptive has been found to
be well tolerated, safe, and effective. This method
was known to be more effective in producing
azoospermia at lower doses.
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TU + Progestine
Norethistrone enanthate 200 mg, a long-acting in-
jectable progestin with weak androgenic and estro-
genic activity, shows great promise as an adjunct
agent in combination with TU (1000 mg) for male
hormonal contraception.7 During a 6-months study
in 40 men, comparing TU alone with TU + norethis-
trone enanthate, combination therapy was found to
be more consistent in producing suppression of
spermatogenesis and serum gonadotropins.10
In phase 2b, WHO conducted a contraceptive trial
on 400 couples using TU and norethistrone enan-
thate injected once every 8 weeks for 48 weeks. This
trial will provide additional data regarding the effi-
cacy, safety, and tolerability of an injectable contra-
ceptive regimen for men.
TE + Progestin
An RCT of levonorgestrel and TE combination has
shown that this combination was superior to TE-
only in achieving azoospermia. Levonogestrel im-
plants (160 μg daily) combined with TE injection,
was known to be more effective than Levonogestrel
(125 μg daily) combined with testosterone patches.7
Injection of depot medroxyprogesterone acetate
(DMPA) and TE also resulted in azoospermia in
98% of subjects.
Combination with GnRH Antagonist3,4
GnRH antagonist regimens have been shown to be
more acceptable in suppressing spermatogenesis
than GnRH agonist, when combined with androgen
agents. GnRH antagonists can suppress FSH and LH
production within hours of administration, and in-
hibit gonadotropin secretion more completely than
agonists.
There have only been a few studies investigating
GnRH antagonist Nal-Glu, administered by daily sub-
cutaneous injections, combined with intramuscular
TE resulting in an azoospermia rate of between 67%
and 93% at 6 to 16 weeks of use. A more recent
study reported that daily cetrorelix combined with
19-nortestosterone-hexyloxyphe-nylpropionate
achieved azoospermia in 100% of subjects by 12
weeks. However, GnRH antagonists have the prob-
lem of needing daily subcutaneous administrations
and being expensive.
Recently, a new long-acting GnRH antagonist
(acyline) given at twice weekly intervals has shown
promise in a small number of subjects producing an
azoospermia rate of 67% at 8 weeks. However, there
are problems with local injection site reactions in-
cluding erythema and induration.
CONCLUSION
The development of an effective, reversible, and ac-
ceptable male hormonal contraceptive is possible.
Until now, combination therapy of androgen and
progestin has been shown to be more effective than
the use of androgen-only regimens or GnRH antago-
nists. However, no male hormonal contraceptive is
currently ready for clinical use, due to limited avail-
able studies. 
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